Sara Fernández Sánchez-Escalonilla, Óscar Esparcia Rodríguez, Sara López Canto, José Miguel Cantero Escribano, Francisco Jesús Molina Cabrero, Ana Gómez-Juárez Sango, Jesús García Guerrero
{"title":"[Vaccination against hepatitis B in patients with inflammatory bowel disease: immune response and associated factors.]","authors":"Sara Fernández Sánchez-Escalonilla, Óscar Esparcia Rodríguez, Sara López Canto, José Miguel Cantero Escribano, Francisco Jesús Molina Cabrero, Ana Gómez-Juárez Sango, Jesús García Guerrero","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Patients with Inflammatory Bowel Disease (IBD) are at increased risk of hepatitis B virus (HBV) infection as well as a lower response to vaccination. This study aimed to analyze the immune response after vaccination against HBV in patients diagnosed with IBD and its associated factors.</p><p><strong>Methods: </strong>A retrospective observational study was conducted on patients with IBD treated at the vaccination clinic for at-risk patients at the <i>Complejo Hospitalario Universitario de Albacete</i> during the period 2011-2018. Immune response after vaccination and associated factors were determined using logistic regression models.</p><p><strong>Results: </strong>231 patients were included. HBV Vaccination had an optimal immune response in 82.7% of the patients. The likelihood of response to vaccination increased in those diagnosed with ulcerative colitis (OR 2.90; 95% CI 1.11-7.61) and decreased with age (80% lower in those aged 40-55 years (OR 0.20; 95% CI 0.05-0.83) and 88% lower in those over 55 years of age (OR 0.12; 95% CI 0.03-0.53) compared to those under 40 years of age) and pharmacological immunosuppression (OR 0.20; 95% CI 0.58-0.71).</p><p><strong>Conclusions: </strong>The decrease in the immunogenicity of the vaccine against hepatitis B in patients with IBD after the beginning of immunosuppressive treatment, as well as with age, make early vaccination a priority in this kind of patients.</p>","PeriodicalId":47152,"journal":{"name":"Revista Espanola De Salud Publica","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2022-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Salud Publica","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Patients with Inflammatory Bowel Disease (IBD) are at increased risk of hepatitis B virus (HBV) infection as well as a lower response to vaccination. This study aimed to analyze the immune response after vaccination against HBV in patients diagnosed with IBD and its associated factors.
Methods: A retrospective observational study was conducted on patients with IBD treated at the vaccination clinic for at-risk patients at the Complejo Hospitalario Universitario de Albacete during the period 2011-2018. Immune response after vaccination and associated factors were determined using logistic regression models.
Results: 231 patients were included. HBV Vaccination had an optimal immune response in 82.7% of the patients. The likelihood of response to vaccination increased in those diagnosed with ulcerative colitis (OR 2.90; 95% CI 1.11-7.61) and decreased with age (80% lower in those aged 40-55 years (OR 0.20; 95% CI 0.05-0.83) and 88% lower in those over 55 years of age (OR 0.12; 95% CI 0.03-0.53) compared to those under 40 years of age) and pharmacological immunosuppression (OR 0.20; 95% CI 0.58-0.71).
Conclusions: The decrease in the immunogenicity of the vaccine against hepatitis B in patients with IBD after the beginning of immunosuppressive treatment, as well as with age, make early vaccination a priority in this kind of patients.
目的:炎症性肠病(IBD)患者感染乙型肝炎病毒(HBV)的风险增加,对疫苗接种的反应较低。本研究旨在分析诊断为IBD的患者接种HBV疫苗后的免疫应答及其相关因素。方法:回顾性观察研究2011-2018年期间在阿尔瓦塞特大学综合医院高危患者疫苗接种诊所接受治疗的IBD患者。采用logistic回归模型确定疫苗接种后的免疫反应及相关因素。结果:纳入231例患者。82.7%的患者接种HBV疫苗获得最佳免疫应答。溃疡性结肠炎患者接种疫苗应答的可能性增加(OR 2.90;95% CI 1.11-7.61),并随着年龄的增长而下降(40-55岁降低80% (OR 0.20;95% CI 0.05-0.83), 55岁以上患者的死亡率降低88% (OR 0.12;95% CI 0.03-0.53)与40岁以下的患者相比)和药理学免疫抑制(OR 0.20;95% ci 0.58-0.71)。结论:IBD患者在开始免疫抑制治疗后,乙型肝炎疫苗的免疫原性下降,且随着年龄的增长,这类患者应优先进行早期接种。